AP Pharma Inc.
123 Saginaw Drive
Redwood City,
CA 94063
United States - Map
Phone: 650-366-2626
Fax: 650-365-6490
Web Site: http://www.appharma.com
| A.P. Pharma, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products using its proprietary polymer-based drug delivery technology. The company’s products include APF530, which is in Phase III clinical trial and is used for the prevention of acute onset and delayed onset chemotherapy-induced nausea and vomiting; and APF112, a Phase II clinical trial product that incorporates the mepivacaine, an anesthetic to provide post-surgical pain relief. Its preclinical products include APF328, a novel formulation for the treatment of pain following orthopedic surgery; APF505, which is a Biochronomer formulation that has the potential to deliver meloxicam within the knee joint for approximately six weeks and to treat the inflammation and pain associated with osteoarthritis; and APF580 to provide analgesia targeted for situations where the intensity and duration of pain require use of an opiate. The company develops Biochronomer technology, which consists of bioerodible polymers designed to release drugs over a defined period. The Biochronomer technology is used for applications in various therapeutic areas, including pain management, prevention of nausea and vomiting, control of inflammation, and treatment of ophthalmic diseases, as well as for DNA/RNAI applications. The company was founded as AMCO Polymerics, Inc. in 1983 and changed its name to Advanced Polymer Systems, Inc. in 1984. Later, it changed its name to A.P. Pharma, Inc. in 2001. The company is based in Redwood City, California. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Gregory H. Turnbull , 69
Interim Chief Financial Officer, Director and Member of Exec. Committee |
N/A
| N/A | Dr. John Barr Ph.D., 48
Sr. VP of R&D |
N/A
| N/A | Mr. Ronald J. Prentki , 50
Chief Exec. Officer, Pres |
N/A
| N/A | Mr. Julian N. Stern , 82
Sec. |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-07
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
2.13% Nasdaq 
Profile
